Tallac Applied Technologies

Tallac Applied Technologies (operating as Tallac Therapeutics) is a privately held biopharmaceutical company focused on developing a novel class of immunotherapy called Immune-modulating Antibody Conjugates (IACs). The company's proprietary TRAAC (Toll-like Receptor Agonist Antibody Conjugate) platform enables the systemic delivery of potent Toll-like receptor 9 (TLR9) agonists directly to the tumor microenvironment and immune cells. Their lead candidate, TAC-001, is a CD22-targeting IAC currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors. By leveraging innate and adaptive immune activation, Tallac aims to provide durable anti-tumor responses for patients who are non-responsive to current checkpoint inhibitors. The company is supported by a strong syndicate of life science investors and is led by an experienced management team with a track record in oncology drug development.